Completed

Phase 1
Age: 18Years +
All Genders
ID00000906

The Effect of HIV Protease Inhibitors on the Stereospecific Metabolism of Methadone in HIV-Infected Subjects

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04

12

Participants Needed

7

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to see if it is safe to combine methadone with two HIV protease inhibitors (PIs), ritonavir (RTV) and saquinavir (SQV), in HIV-infected patients not currently taking PIs. This study will measure the interactions between methadone and the PIs. Methadone is used treat addicts and to treat severe pain. In order to find the safest way to use methadone with PIs, it is important to evaluate how they interact.

CONDITIONS

Official Title

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Inclusion Criteria

You may be eligible for this study if you:

  • Are HIV-positive and have an HIV RNA count below 100,000 copies/ml within 30 days prior to study entry.
  • Are taking methadone.
  • Are at least 18 years old.
  • Are within 40% of your ideal body weight and weigh at least 99 lbs.

Exclusion Criteria

You will not be eligible for this study if you:

  • Are allergic to or are unable to take RTV or SQV.
  • Have a history of treatment failure with indinavir, RTV, or SQV.
  • Have a history of certain illnesses that might prevent you from completing the study.
  • Have severe diarrhea or other stomach problems.
  • Have taken any PI within 4 weeks prior to study entry.
  • Would be unable to complete the study due to alcohol or drug abuse.
  • Are co-enrolled in other protocols that have you taking medications that are prohibited in this study.
  • Are taking PIs other than RTV or SQV.
  • Are receiving certain therapies or are taking certain medications, including experimental drugs.
  • Have an active opportunistic (AIDS-related) infection or disease that requires medication within 14 days prior to study entry.
  • Are pregnant or breast-feeding.
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Total: 7 locations

1

San Francisco Gen Hosp

San Francisco, California, United States, 941102859

Status Unknown

2

Univ of Colorado Health Sciences Ctr

Denver, Colorado, United States, 80262

Status Unknown

3

Johns Hopkins Hosp

Baltimore, Maryland, United States, 21287

Status Unknown

4

Beth Israel Med Ctr

New York, New York, United States, 10003

Status Unknown

5

Chelsea Ctr

New York, New York, United States, 10021

Status Unknown

6

Cornell Univ Med Ctr

New York, New York, United States, 10021

Status Unknown

7

Mount Sinai Med Ctr

New York, New York, United States, 10029

Status Unknown

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

TREATMENT

Number of Arms

0

Similar Trials

ACTION HIV: A Global Record of Anal Squamous Cell Carcinoma ...

Anal Squamous Cell Carcinoma

Actively Recruiting

1 location

Long-term Follow-up Study of HIV-infected Individuals in HIV...

HIV Infections

Actively Recruiting

1 location

Evaluation of Oral VH4524184 with Emtricitabine and Tenofovi...

HIV Infections

Actively Recruiting

113 locations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.

J G Gerber, S Rosenkranz, Y Segal...

https://pubmed.ncbi.nlm.nih.gov/11404537